Clincosm LogoSign in Get a demo

metastatic castrate resistant prostate cancer

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castrate Resistant Prostate Cancer, BRCA1, BRCA2, PALB2 Genetic Mutations Trial in United States (Carboplatin,

Recruiting
  • Metastatic Castrate Resistant Prostate Cancer
  • +2 more
  • West Los Angeles, California
  • +13 more
Nov 23, 2022

Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma Trial in Worldwide (MGC018, retifanlimab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +5 more
  • MGC018
  • retifanlimab
  • Santa Monica, California
  • +19 more
Feb 14, 2022

Metastatic Castrate Resistant Prostate Cancer Trial in Boston, Detroit, Columbus (Docetaxel, Radium 223)

Recruiting
  • Metastatic Castrate Resistant Prostate Cancer
  • Boston, Massachusetts
  • +3 more
Feb 22, 2022

ARv7 in Plasma of Advanced Metastatic Castrate Resistant

Active, not recruiting
  • Metastatic Castrate Resistant Prostate Cancer
    • New Haven, Connecticut
      Yale University School of Medicine
    Sep 29, 2021

    Metastatic Castrate Resistant Prostate Cancer Trial in Worldwide (Masitinib, Docetaxel, Prednisone)

    Completed
    • Metastatic Castrate Resistant Prostate Cancer
    • Sherbrooke, Canada
    • +8 more
    Jun 3, 2021

    Metastatic Castrate Resistant Prostate Cancer Trial in Worldwide (Tasquinimod, Placebo)

    Terminated
    Has Results
    • Metastatic Castrate Resistant Prostate Cancer
    • Gent, Belgium
    • +57 more
    Nov 21, 2019

    Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer Trial run by the NCI (TRC105)

    Completed
    Has Results
    • Prostate Cancer
    • Metastatic Castrate Resistant Prostate Cancer
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 13, 2018